PROJECT SUMMARY/ABSTRACT
Soon after birth, most infants develop the optimal refractive error (i.e., “clinical” emmetropia) in both eyes that
is maintained throughout childhood and into adult life. However, for reasons not currently understood, a
significant and rapidly increasing proportion of the population develop myopia, or nearsightedness. Because of
structural changes that take place as the eye becomes myopic, even low degrees of myopia pose a significant
risk for multiple blinding conditions. As a consequence, myopia is now one of the leading causes of permanent
visual impairment in the world. Additionally, myopia represents a substantial economic burden. In addition to
lost productivity, billions of dollars are spent annually on optical corrections and pathologies caused by myopia.
The long-term goal of our research program is to provide a better understanding of the etiology of common
forms of myopia, juvenile and early adult-onset myopia, and to develop effective treatment strategies that
reduce the burden of myopia. The specific aims of our proposed research are to determine how visual
experience affects refractive development, to characterize the operational properties of the vision-dependent
mechanisms that regulate eye growth, and to explore new pharmaceutical approaches to eliminate myopia.
Our purpose is to generate knowledge that can be applied to the human eye; however, many of the required
experiments cannot be conducted in humans. Therefore, these experiments will be conducted using rhesus
monkeys. Previous studies in our lab and others show that characteristics of light, such as intensity,
wavelength, and duration of exposure, influence eye growth. Potential mechanisms include alterations in
retinal and choroidal visual cascades and ocular remodeling, particularly of the sclera, the outermost coat of
the eye. Preliminary data also show that prostaglandin analogs and alpha-adrenergic agonists influence eye
growth. Here, controlled rearing strategies, rigorous optical and biometric techniques, and histopathological
investigation will be used to determine: 1) the effects of duration and dosing of red light exposure on in vivo
eye growth and myopia and on in vitro human scleral fibroblast culture and 2) whether prostaglandin analogs
and alpha-2 adrenergic agonists can slow the development of myopia. The role of scleral fibroblast activity,
scleral remodeling, and intraocular pressure in eye growth will be examined. The proposed experiments focus
on fundamental issues concerning the manner in which visual experience influences refractive development.
Findings will be important in determining how and to what extent visual experience contributes to the genesis
of common human refractive errors. More importantly, the results of these studies will potentially provide the
scientific foundation for novel treatment and management strategies for the most common forms of myopia in
children to prevent and slow the progression of myopia, increase quality of life, reduce the risk of associated
pathologies, and decrease the economic burden caused by myopia.
Public Health Relevance Statement
PROJECT NARRATIVE
Myopia, or nearsightedness, is a significant public health concern because, in addition to the high costs and
the complications associated with traditional optical and surgical correction strategies, myopia can lead to
permanent vision loss and ocular abnormalities causing blindness. Moreover, recent evidence suggests that
the prevalence of myopia and, consequently, its impact are increasing rapidly. Hence, we aim to develop
urgently needed treatment strategies to prevent and reduce the degree of myopia.
No Sub Projects information available for 5R01EY003611-41
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01EY003611-41
Patents
No Patents information available for 5R01EY003611-41
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01EY003611-41
Clinical Studies
No Clinical Studies information available for 5R01EY003611-41
News and More
Related News Releases
No news release information available for 5R01EY003611-41
History
No Historical information available for 5R01EY003611-41
Similar Projects
No Similar Projects information available for 5R01EY003611-41